NCT05200936Phase 2Completed

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

Study sponsor: Definium Therapeutics US, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-11-06Actual

Enrollment · participants53Actual

Source updated2026-02-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

ADHD; Attention Deficit Disorder

Treatments or interventions studied

MM120DrugAlso known as MM-120, DT120, lysergide tartrate

Primary outcomes · main study measures

Read the study measures

measure: Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms; description: The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.; timeFrame: 6 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history